The U.S. FDA has approved the priority sNDA for a new first-line maintenance therapy in extensive-stage small-cell lung cancer from Jazz Pharmaceuticals plc. Zepzelca (lurbinectedin) can now be combined with Tecentriq (atezolizumab, Roche AG) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Roche) as a maintenance therapy for adults who haven\u2019t progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.<\/p>\n
BioWorld<\/a> Regulatory<\/a> Cancer<\/a> Small molecule<\/a> U.S.<\/a> FDA<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"The U.S. FDA has approved the priority sNDA for a new first-line maintenance therapy in extensive-stage small-cell lung…\n","protected":false},"author":2,"featured_media":13658,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[6717,8086,2112,9980,9979,4337,9976,9978,4180,134,4178,8095,9975,7780,9981,2278,9977],"class_list":{"0":"post-13657","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-atezolizumab","9":"tag-bioworld","10":"tag-cancer","11":"tag-combination-therapy","12":"tag-extensive-stage-small-cell-lung-cancer","13":"tag-fda","14":"tag-jazz-pharmaceuticals-plc","15":"tag-lurbinectedin","16":"tag-regulatory","17":"tag-roche","18":"tag-roche-ag","19":"tag-small-molecule","20":"tag-small-cell-lung-cancer","21":"tag-tecentriq","22":"tag-tecentriq-hybreza","23":"tag-u-s","24":"tag-zepzelca"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/13657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=13657"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/13657\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/13658"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=13657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=13657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=13657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}